

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



PRELIMINARY PROGRAMME

Wednesday, 28 October 2026
(All times in CET)

12:00 – 14:00	Lymphoma Working Party Scientific Business Meeting (part I)	
12:00 – 14:00	Cellular Therapy and Immunobiology Working Party Scientific Business Meeting	
14:00 – 15:00	Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Scientific Business Meeting	
15:00 – 17:00	Lymphoma Working Party Scientific Business Meeting (part II)	
17:00 – 17:30	Coffee Break	
17:30 – 17:45	Welcome and Opening Remarks Ali Bazarbachi (LB), Jürgen Kuball (NL), Peter Dreger (DE)	
17:45 – 18:30	Keynote Lecture Chairs: Ali Bazarbachi (LB), Jürgen Kuball (NL)	
17:45-18:30	The future of cellular therapy in lymphoma	Anna Sureda (ES)

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



PRELIMINARY PROGRAMME

Thursday, 29 October 2026
(All times in CET)

08:00 – 09:30 Session I — Aggressive lymphomas

Chairs: Bertram Glass (DE) & Ali Bazarbachi (LB)

08:00-08:20	New classifiers: does it matter for treatment	
08:20-08:40	Sequencing of cellular therapies in DLBCL (CAR, Bispcs, auto, allo)	Bertram Glass (DE)
08:40-09:00	Burkitt Lymphoma: current management standards and role of cellular therapy	Mahmoud Aljurf (SA)
09:00-09:10	Case presentation: Multimodal treatment of EBV-positive post-transplant lymphoproliferative disease including Tabelecleucel after allogeneic hematopoietic cell transplantation	Kiavasch Farid (DE)
09:10-09:30	Case and Session Discussion	
09:30 – 10:00	Coffee Break	

10:00 – 11:30 Session II — Follicular lymphoma and Mantle cell lymphoma

Chairs: Simona Pagliuca (FR) & Peter Dreger (DE)

10:00-10:20	Sequencing of cellular therapies in FL (CAR, Bispcs, auto, allo)	Luca Castagna (IT)
10:20-10:40	Sequencing of cellular therapies in MCL (CAR, Bispcs, auto, allo)	Olivier Hermine (FR)
10:40-11:00	MRD in FL and MCL: implications for prognosis and pre-emptive intervention	Christiane Pott (DE)
11:00-11:10	Case presentation: Second-line brexucabtagene autoleucel for mantle cell lymphoma with rapid progression on frontline acalabrutinib-based therapy: complete metabolic response complicated by severe ICANS and concurrent embolic stroke	Fernando Gibran-Nunes (BR)
11:10-11:30	Case and Session Discussion	

11:30 – 12:30 Session III — New targets and microbiota

Chair: Alex Rampotas (UK)

11:30-11:50	Impact of the microbiota on CAR T cell efficacy	Hendrick Poeck (DE)
11:50-12:10	Development of a First-in-Class CAR-T Therapy Against Calreticulin-Mutant Neoplasms	Alex Rampotas (UK)
12:10-12:20	Case presentation: Investigating the role of CAR-T cell Secretome and Extracellular Vesicles in B-Cell Aplasia	Besjana Xhahysa (IT)
12:20-12:30	Case and Session Discussion	
12:30 – 13:30	Lunch Break	

13:30 – 14:15 Industry Symposium

14:15 – 16:15 Session IV — Management of CART and Autoimmune Landscape

Chairs: Jürgen Kuball (NL) & Chara Kyriakou (UK)

14:15-14:35	CAR T activity for autoimmune diseases across EBMT centers	
14:35-14:55	The landscape of immune monitoring in CAR-T cell therapy	Simona Pagliuca (FR)
14:55-15:15	CAR T and impact on Quality of Life	Anne Spanjaart (NL)
15:15-15:35	Fertility recovery and management after CAR T therapies	Giorgio Orofino (IT)
15:35-15:45	Case Presentation: Managing CPI and CAR-T in young patient with refractory primary mediastinal diffuse large B-cell lymphoma: a case of pericarditis	
15:45-16:15	Case and Session Discussion	Ambra Fumagalli (IT)

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



PRELIMINARY PROGRAMME

Thursday, 29 October 2026 - continued
(All times in CET)

16:15 – 16:45	Coffee Break	
16:45 – 18:15	Session V — CART outcome predictors and late effects Chairs: Jürgen Kuball (NL) & Vanderson Rocha (BR)	
16:45-17:05	Prognostic Scores and outcome predictors (CAR-Hematotox, EASIX, ICAHT) in CART therapy and beyond	Ana Alarcón (ES)
17:05-17:25	Frailty and eligibility criteria in CAR T recipients	Vanderson Rocha (BR)
17:25-17:45	Secondary malignancies from the EBMT registry	Isabel Sánchez-Ortega (ES)
17:45-17:55	Case Presentation: CAR-T-induced persistent bone marrow aplasia requiring emergency haploidentical transplantation in TP53-mutated mantle cell lymphoma with spinal and cutaneous relapse	Roberto Bono (IT)
17:55-18:15	Case and Session Discussion	

Joint Lymphoma Working Party and Cellular Therapy and Immunobiology Working Party Educational Meeting

Heidelberg, Germany | 28-30 October 2026



PRELIMINARY PROGRAMME

Friday, 30 October 2026
(All times in CET)

08:00 – 09:30 Session VI — T-cell lymphoma

Chairs: Gandhi Damaj (FR) & Anna Sureda (ES)

08:00-08:20 Molecular Pathology of T-cell lymphoma

08:20-08:40 The role of autologous and allogeneic Transplantation in PTCL-NOS, nTFHL, ALCL

Norbert Schmitz (DE)

08:40-09:00 The role of autologous and allogeneic Transplantation in rare TCL (HSTL, ENKTL, EATL, MEITL, ATLL, CTCL)

Eva Domingo (ES)

09:00-09:10 Case presentation: Ruxolitinib-based strategies in monomorphic epitheliotropic intestinal

T-cell lymphoma (MEITL): sustained survival beyond 18 months despite multiple relapses

Jorge Illarramendi (FR)

09:10-09:30 Case and Session Discussion

09:30 – 10:15 Industry Symposium

10:15 – 10:45 Coffee Break

10:45 – 12:15 Session VII — Hodgkin lymphoma

Chairs: Ali Bazarbachi (LB) & Alina Tanase (RO)

10:45-11:05 Is auto-HCT needed in all RR cHL patients?

Carmen Martínez (ES)

11:05-11:25 The role of allo-HCT in cHL in 2026

Ali Bazarbachi (LB)

11:25-11:45 The role of CART Cells in RR HL

Ana Carolina Caballero (ES)

11:45-11:55 Case presentation: Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in

Patients with Relapsed/Refractory Hodgkin Lymphoma in Real-World Clinical

Practice: A Single-Center Experience in Kazakhstan

Dana Sailaubekova (KZ)

11:55-12:15 Case and Session Discussion

12:15 – 12:30 Closing Remarks

Ali Bazarbachi (LB), Jürgen Kuball (NL), Peter Dreger (DE)